Compendium of Cancer Genome Aberrations

Changes

HAEM5:Volunteer Assignments and Opportunities (view source)

Revision as of 14:46, 17 December 2023

532 bytes added ,  14:46, 17 December 2023
no edit summary
Line 2: Line 2:  
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
 
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
 
|-
 
|-
−
!Disease (5th Edition)!!Page Type!!Author!!Date Assigned to Author!!Target Completion Date!!Author Content (Pending or Complete)!!Date Completed by Author!!Associate Editor!!Date of Last Editor Review
+
!Disease (5th Edition)!!Page Type!!Author (5th edition)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Author Content (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review!!Notes
−
!Correlated Prior Disease Name (4th Edition)!!Notes
+
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 
|-
 
|-
 
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
 
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
Line 10: Line 11:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 19: Line 21:  
|
 
|
 
|-
 
|-
−
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)||
+
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR||
+
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Chronic myeloid leukaemia||Disease||Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||FQR||
+
|Chronic myeloid leukaemia||Disease||Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally|| || || || ||FQR||
+
|Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff  Pending Review*|| || || || ||FQR||
+
|Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff  Pending Review*|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center|| || || || ||FQR||
+
|Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR||
+
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR||
+
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR||
+
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR||
+
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR||
+
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR||
+
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR||
+
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR||
+
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR||
+
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR||
+
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR||
+
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR||
+
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
+
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
+
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
+
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR||
+
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR||
+
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR||
+
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR||
+
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR||
+
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR||
+
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR||
+
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR||
+
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR||
+
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR||
+
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR||
+
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
 
|Acute promyelocytic leukaemia with PML::RARA fusion
 
|Acute promyelocytic leukaemia with PML::RARA fusion
Line 123: Line 157:  
|
 
|
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 +
|
 
|
 
|
 
|
 
|
Line 135: Line 170:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 147: Line 183:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 159: Line 196:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 171: Line 209:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 183: Line 222:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 195: Line 235:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 207: Line 248:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 219: Line 261:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 231: Line 274:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 243: Line 287:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 255: Line 300:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 267: Line 313:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 279: Line 326:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 291: Line 339:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 303: Line 352:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 315: Line 365:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 327: Line 378:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 339: Line 391:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 351: Line 404:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 363: Line 417:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 375: Line 430:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 387: Line 443:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 399: Line 456:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 411: Line 469:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 423: Line 482:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 435: Line 495:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 447: Line 508:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 459: Line 521:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 471: Line 534:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 483: Line 547:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 495: Line 560:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 507: Line 573:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 516: Line 583:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 533: Line 601:  
|
 
|
 
|Greg Corboy (GC)
 
|Greg Corboy (GC)
 +
|
 
|
 
|
 
|
 
|
Line 545: Line 614:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 557: Line 627:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 569: Line 640:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 581: Line 653:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 593: Line 666:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 605: Line 679:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 617: Line 692:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 629: Line 705:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 641: Line 718:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 653: Line 731:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 662: Line 741:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 679: Line 759:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 691: Line 772:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 703: Line 785:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 715: Line 798:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 727: Line 811:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 739: Line 824:  
|
 
|
 
|Holli Drendel (HD)
 
|Holli Drendel (HD)
 +
|
 
|
 
|
 
|
 
|
Line 751: Line 837:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 763: Line 850:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 775: Line 863:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 787: Line 876:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 799: Line 889:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 811: Line 902:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 823: Line 915:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 835: Line 928:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 847: Line 941:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 859: Line 954:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 871: Line 967:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 883: Line 980:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 895: Line 993:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 900: Line 999:  
|-
 
|-
 
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
 
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
 +
| ||
 +
|
 
|
 
|
−
| ||
   
|-
 
|-
−
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG||
+
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG||
+
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG||
+
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG||
+
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
 
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli
 
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli
Line 923: Line 1,027:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 935: Line 1,040:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 947: Line 1,053:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 959: Line 1,066:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 971: Line 1,079:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 983: Line 1,092:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 995: Line 1,105:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,007: Line 1,118:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,019: Line 1,131:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,031: Line 1,144:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,043: Line 1,157:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,055: Line 1,170:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,067: Line 1,183:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,079: Line 1,196:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,091: Line 1,209:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC||
+
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC||
+
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC||
+
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC||
+
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC||
+
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC||
+
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC||
+
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC||
+
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC||
+
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC||
+
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC||
+
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC||
+
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC||
+
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC||
+
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC||
+
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC||
+
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC||
+
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC||
+
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC||
+
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Primary effusion lymphoma||Disease|| || || || || ||GC||
+
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC||
+
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC||
+
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC||
+
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC||
+
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC||
+
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC||
+
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC||
+
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC||
+
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC||
+
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
 
|Cold agglutinin disease
 
|Cold agglutinin disease
Line 1,190: Line 1,338:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG||
+
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG||
+
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
 
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
 
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
 +
| ||
 +
|
 
|
 
|
−
| ||
   
|-
 
|-
 
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
 
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
 +
| ||
 +
|
 
|
 
|
−
| ||
   
|-
 
|-
 
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
 
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
 +
| ||
 +
|
 
|
 
|
−
| ||
   
|-
 
|-
 
|Mu heavy chain disease||Disease|| || || || || ||SG
 
|Mu heavy chain disease||Disease|| || || || || ||SG
 +
| ||
 +
|
 
|
 
|
−
| ||
   
|-
 
|-
 
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
 
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
 +
| ||
 +
|
 
|
 
|
−
| ||
   
|-
 
|-
 
|Alpha heavy chain disease||Disease|| || || || || ||SG
 
|Alpha heavy chain disease||Disease|| || || || || ||SG
 +
| ||
 +
|
 
|
 
|
−
| ||
   
|-
 
|-
 
|Plasmacytoma||Disease|| || || || || ||SG
 
|Plasmacytoma||Disease|| || || || || ||SG
 +
| ||
 +
|
 
|
 
|
−
| ||
   
|-
 
|-
 
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
 
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
 +
| ||
 +
|
 
|
 
|
−
| ||
   
|-
 
|-
 
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
 
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
 +
| ||
 +
|
 
|
 
|
−
| ||
   
|-
 
|-
 
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
 
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
Line 1,241: Line 1,401:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 1,251: Line 1,412:  
|-
 
|-
 
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
 
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
 +
| ||
 +
|
 
|
 
|
−
| ||
   
|-
 
|-
−
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK||
+
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK||
+
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD||
+
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
 
|Early T-precursor lymphoblastic leukaemia / lymphoma
 
|Early T-precursor lymphoblastic leukaemia / lymphoma
Line 1,271: Line 1,436:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,283: Line 1,449:  
|
 
|
 
|SK
 
|SK
 +
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK||
+
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK||
+
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK||
+
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK||
+
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK||
+
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK||
+
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK||
+
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK||
+
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK||
+
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK||
+
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK||
+
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK||
+
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK||
+
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK||
+
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK||
+
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK||
+
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK||
+
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK||
+
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK||
+
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK||
+
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK||
+
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK||
+
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK||
+
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK||
+
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK||
+
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK||
+
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK||
+
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK||
+
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK||
+
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Severe mosquito bite allergy||Disease|| || || || || ||SK||
+
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK||
+
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Systemic chronic active EBV disease||Disease|| || || || || ||SK||
+
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK||
+
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
 
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
 
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
Line 1,391: Line 1,591:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 1,408: Line 1,609:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,420: Line 1,622:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,432: Line 1,635:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,444: Line 1,648:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,456: Line 1,661:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,468: Line 1,674:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,480: Line 1,687:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,489: Line 1,697:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 1,498: Line 1,707:  
|
 
|
 
|-
 
|-
−
|Fanconi anaemia||Disease|| || || || || ||NA||
+
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Bloom syndrome||Disease|| || || || || ||NA||
+
|Bloom syndrome||Disease|| || || || || ||NA|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA||
+
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
−
| ||
+
|
 +
|
 
|-
 
|-
−
|RASopathies||Disease|| || || || || ||NA||
+
|RASopathies||Disease|| || || || || ||NA|| ||
−
| ||
+
|
 +
|
 
|}
 
|}
Retrieved from "https://content.ccga.io/index.php/Special:MobileDiff/13896"